FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to liquid suspensions containing tasimelteon. The pharmaceutical composition of tasimelteon is a homogeneous aqueous suspension and contains tasimelteon at a concentration of 1 to 6 mg/ml; a suspending agent containing microcrystalline cellulose and sodium carboxymethylcellulose, at a concentration of 10 to 30 mg/ml; taste masking agent; opacity agent; and surfactant. Also the following is disclosed: homogeneous aqueous suspensions containing tasimelteon.
EFFECT: group of inventions provides a stable homogeneous aqueous suspension of tasimelteon.
13 cl, 2 dwg, 3 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL SUSPENSIONS, WHICH DO NOT CONTAIN COLOURING AGENTS, AND METHODS OF OBTAINING THEM | 2005 |
|
RU2395275C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
| TABLET COMPOSITION COMPRISING CINACALCET HYDROCHLORIDE | 2013 |
|
RU2662562C2 |
| EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION | 2019 |
|
RU2810789C2 |
| COMPOSITIONS AND METHODS OF ACTIVE PHARMACEUTICAL INGREDIENT STABILISATION | 2005 |
|
RU2391115C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING IBUPROFEN AND DOMPERIDONE FOR MIGRAINE TREATMENT | 1998 |
|
RU2195935C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING 5-METHYL-2-(2′-CHLORO-6′- FLUOROANILINE)PHENYLACETIC ACID | 2004 |
|
RU2363462C2 |
| POWDER ANTIBACTERIAL COMPOSITION CONTAINING HYDRATED CEFTIBUTEN FOR ORAL USING AS A SUSPENSION | 1993 |
|
RU2123863C1 |
| COMPOSITION FOR ORAL CARE WITH HIGH WATER CONTENT, INCLUDING MICROCRYSTALLINE CELLULOSE AND CARBOXYMETHYLCELLULOSE | 2012 |
|
RU2623140C2 |
| LIQUID ORAL PHARMACEUTICAL DOSAGE FORM | 2019 |
|
RU2810115C2 |
